Endothelial cells were plated at a density of 2.5 × 104 cells in a 96-well plate, and after 24 h were pretreated 1 h before and during the experiment with the non-specific pharmacological TRPM7 blockers, 2-Aminoethoxydiphenyl borate (2-APB) (100 µM (Sigma, USA)) and Carvacrol (0.732 M, (Sigma, USA)), the TRPM7 α-kinase domain inhibitor TG100-115 (1 µM (STCB, USA)), the vWF inhibitor Caplacizumab (0.8 µg/mL, (MCE, USA)), the ICAM-1 inhibitor A-286982 and A-205804 (25 nM and 25 nM, respectively (STCB, USA)), or the P-Sel inhibitor KF38789 (50 nM (STCB, USA)), or transfected with an siRNA against TRPM7 (siRNATRPM7) or a non-targeting siRNA (siRNANontarget). In brief, cells were plated overnight in 96-well or 6-well plates and transfected with 5 nmol/L siRNA (Dharmacon) using lipofectamine (Invitrogen) and Opti-MEM (Gibco) according to manufacturer instructions for 4 h. Experiments were performed 48 h after transfection. To start the assay, LPS (O127:B8, Sigma-Aldrich) was added at a final concentration of 20 µg/mL with fluorescent-labeled platelets (~ 2.25 × 106 platelets per well, contained in 100 µL of minimal experimentation medium) for 24 h at 37 ℃. Platelets were stained with the green fluorescent dye vibrant DiO (ThermoFisher Scientific) for 15 min at 37 °C. Then, non-adherent platelets were washed thrice with warm phosphate-buffered saline (PBS) and observed in the FLoid Cell Imaging Station (ThermoFisher Scientific). This experiment was performed in technical triplicate, and six fields for each condition were analyzed.
Free full text: Click here